MARKET

NTRA

NTRA

Natera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.62
+3.74
+5.76%
Closed 16:30 09/25 EDT
OPEN
65.18
PREV CLOSE
64.88
HIGH
71.08
LOW
64.42
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
71.08
52 WEEK LOW
16.87
MARKET CAP
5.76B
P/E (TTM)
-34.4201
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Medicare Issues Draft Local Coverage Determination for Signatera in Immunotherapy Response Monitoring
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has issued a draft local coverage determination (LCD) to provide expanded coverage for circulating tumor DNA (ctDNA) tests that detect MRD in patients
PR Newswire · 3d ago
Natera Announces Medicare Issues Draft Local Coverage Determination For Signatura In Immunotherapy Response Monitoring
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring SAN CARLOS, Calif., Sept. 24, 2020 /PRNewswire/ --Natera, Inc.(NASDAQ:NTRA), a pioneer and global
Benzinga · 3d ago
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society for Medical Oncology (ESMO) virtual meeting taking place September 19-21, 2020
PR Newswire · 09/18 14:03
Natera Reports Will Present New Data On Personalized Molecular Residual Disease Test, Signatera, At European Society For Medical Oncology Sept. 19-21
 Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020
Benzinga · 09/18 13:04
Benzinga's Top Upgrades, Downgrades For September 17, 2020
Upgrades * Goldman Sachs upgraded the previous rating for Mercury Systems Inc (NASDAQ: MRCY) from Neutral to Buy. For the fourth quarter, Mercury Systems had an EPS of $0.72, compared to year-ago quarter EPS of $0.47. The current stock performance of Mercury Systems shows a 52-week-high of $96.29 and
Benzinga · 09/17 13:41
Natera Highlights Launch Of Initiative To Transform Mgmt. Of Cancer Patients In Organ Transplants
 Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera™ test
Benzinga · 09/14 13:09
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera™ test for molecular residual disease (MRD) assessment pre- and post-transplant, in combination with the
PR Newswire · 09/14 13:03
Natera's Signatera MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide Medicare benefits for serial use of the Signatera molecular
PR Newswire · 09/11 14:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTRA. Analyze the recent business situations of Natera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTRA stock price target is 71.43 with a high estimate of 82.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 291
Institutional Holdings: 91.45M
% Owned: 109.02%
Shares Outstanding: 83.88M
TypeInstitutionsShares
Increased
99
6.03M
New
67
1.78M
Decreased
51
7.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.16%
Healthcare Equipment & Supplies
+2.01%
Key Executives
Chairman/Co-Founder/Director
Matthew Rabinowitz
President/Chief Executive Officer/Director
Steven Chapman
Co-Founder/Chief Technology Officer/Director
Jonathan Sheena
Chief Financial Officer/IR Contact Officer
Michael Brophy
Chief Operating Officer
Robert Schueren
Lead Director/Independent Director
Roelof Botha
Independent Director
Roy Baynes
Independent Director
Rowan Chapman
Independent Director
Todd Cozzens
Independent Director
James Healy
Independent Director
Gail Marcus
Independent Director
Herman Rosenman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NTRA
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.